Maraviroc intensification for suboptimal CD4+T cell response in a perinatally HIV-infected adolescent

AIDS

Volumn 25, Issue 9, 2011, Pages 1243-1244

  Espiau, María ^a   Soler Palacín, Pere ^a   Paredes, Roger ^b   Martín Nalda, Andrea ^a   Bargalló, Eva ^a   Figueras, Concepció ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b AIDS Research Institute IrsiCaixa HIVACAT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; MARAVIROC; ZIDOVUDINE;

ADOLESCENT; ANTIVIRAL THERAPY; CASE REPORT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PATIENT COMPLIANCE; PERINATAL INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; CD4-POSITIVE T-LYMPHOCYTES; CYCLOHEXANES; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRIAZOLES;

EID: 79957634073     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283474187     Document Type: Letter

References (7)

1. Battegay M, Nüesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
2. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4R cell rises in HIV-infected patients. PLoS One 2010; 5:e13188.
3. Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010. [Epub ahead of print]
4. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007; 12:1097-1106. (Pubitemid 350114990)
5. Poveda E, Alcaḿ J, Paredes R, Córdoba J, Gutiérrez F, Llibre JM, et al. Genotypic determination of HIV tropism: clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010; 12:135-148.
6. Stepanyuk O, Chiang TS, Dever LL, Paez SL, Smith SM, Perez G, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009; 23:1911-1913.
7. Wilkin T, Lalama C, Tenorio A, Landay A, Ribaudo H, McKinnon J, et al. Maraviroc intensification for suboptimal CD4R cell response despite sustained virologic suppression: ACTG 5256 [abstract 285]. In: 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, USA.